In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Verona Pharma (VRNA – Research Report), with a price target of $25.00. The company’s shares closed last Wednesday at $6.88.
According to TipRanks.com, Moussatos has 0 stars on 0-5 stars ranking scale with an average return of -4.5% and a 33.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, BioMarin Pharmaceutical, and Pacira Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Verona Pharma with a $21.60 average price target, representing a 206.4% upside. In a report issued on January 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $25.00 price target.
Based on Verona Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $40 million and net profit of $11.05 million. In comparison, last year the company had a GAAP net loss of $18.93 million.
Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VRNA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.
Read More on VRNA:
- Analysts’ Top Healthcare Picks: Albireo Pharma (ALBO), Cogent Biosciences (COGT)
- Spruce Biosciences (SPRB) Gets a Buy Rating from H.C. Wainwright
- H.C. Wainwright Remains a Buy on Uranium Royalty Corp (UROY)
- William Blair Initiates a Buy Rating on Nkarta (NKTX)
- H.C. Wainwright Maintains a Buy Rating on Sutro Biopharma (STRO)